Qiagen N.V.

QGEN

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2024-12-02 pm EST			5-day change	1st Jan Change
43.65 ^USD	+0.51%		+0.92%	-2.51%

Nov. 29	Qiagen Plans to Open New Facility in Spain in 2026	MT
Nov. 27	QIAGEN Launches Novel Tools for Customizing Digital PCR Assays and NGS Panels for Microbial Analysis	CI

QIAGEN NV : Deutsche Bank reaffirms its Buy rating

November 07, 2024 at 08:34 am EST

Deutsche Bank is positive on the stock with a Buy rating.

Latest news about Qiagen N.V.

Qiagen Plans to Open New Facility in Spain in 2026	Nov. 29	MT
QIAGEN Launches Novel Tools for Customizing Digital PCR Assays and NGS Panels for Microbial Analysis	Nov. 27	CI
Qiagen N.V. Presents at 6th Annual Wolfe Research Healthcare Conference 2024, Nov-20-2024 12:40 PM	Nov. 20
QIAGEN NV : Jefferies is Neutral	Nov. 20	ZD
Qiagen N.V. Presents at Jefferies London Healthcare Conference 2024, Nov-20-2024 09:00 AM	Nov. 20
Qiagen N.V. Presents at Stifel 2024 Healthcare Conference, Nov-19-2024 09:00 AM	Nov. 19
Qiagen Partners With McGill University for Microbiome Research	Nov. 13	MT
Qiagen, McGill University Enter Partnership Deal for Microbiome Research Development	Nov. 13	MT
Qiagen Collaborates with McGill University to Advance Microbiome Research	Nov. 12	CI
QIAGEN NV : UBS reiterates its Neutral rating	Nov. 11	ZD
Qiagen N.V., Q3 2024 Earnings Call, Nov 07, 2024	Nov. 07
QIAGEN NV : Deutsche Bank reaffirms its Buy rating	Nov. 07	ZD
QIAGEN : Markets hailed the Q3 beat + the profitability upgrade	Nov. 07
QIAGEN NV : Receives a Buy rating from Berenberg	Nov. 07	ZD
Qiagen Q3 Adjusted Earnings, Revenue Increase; Raises 2024 Adjusted Earnings Guidance	Nov. 07	MT
QIAGEN NV : UBS reaffirms its Neutral rating	Nov. 07	ZD
Qiagen N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 06	CI
Diagnostics firm Qiagen reports rise in third-quarter revenue	Nov. 06	RE
Qiagen N.V. Reaffirms Earnings Guidance for the Full Year 2024	Nov. 06	CI
QIAGEN Says FDA Cleared QIAstat-Dx Panel for Meningitis/Encephalitis	Nov. 04	MT
Qiagen Secures US FDA Nod for Meningitis, Encephalitis Panel	Nov. 04	MT
QIAGEN Receives FDA Clearance of QIAstat-Dx Meningitis/Encephalitis Panel to Support Emergency Diagnostics	Nov. 04	CI
QIAGEN Says QIAstat-Dx Respiratory Test Receives FDA Clearance	Oct. 29	MT
QIAGEN Receives FDA Clearance for QIAstat-Dx Mini Panel to Improve Precision in Outpatient Respiratory Treatment	Oct. 29	CI
HSBC Downgrades QIAGEN to Hold From Buy, Price Target is $49	Oct. 17	MT

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Employees

5,800

Sector

Biotechnology & Medical Research

Calendar

2024-12-04 - Citi Global Healthcare Conference

More about the company